Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
AssigneeThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
InventorsJeffrey Schlom, Elene Barzaga, Sam Zaremba
Life of this patent
Estimating the term…
Abstract
A peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence is described. Pharmaceutical compositions, peptide-immunoglobulin conjugates, kits and peptide-carrier molecules comprising such peptides also are described.
Claims43
A peptide comprising an agonist of a native sequence:
- 7 YLSGANLNL (Seq. ID No:
- 1) | | 123456789
A peptide consisting of the amino acid sequence YLSGADLNL (Seq. ID No:
- 2), YLSGADINL (Seq. ID No:
- 3), or YLSGANINL (Seq. ID No:
- 4), YLSGACLNL (Seq. ID No:
- 5).
An isolated DNA encoding a peptide containing Seq. ID No:
- 2, Seq. ID No:
- 3, Seq. ID No:
- 4, Seq. ID No:
- 5, or combinations thereof.
An isolated DNA comprising a nucleotide sequence of SEQ. ID No:
- 7 or 8.
A peptide comprising an antagonist of a native sequence:
- YLSGANLNL (Seq. ID No:
- 1) wherein the antagonist varies at at least one amino acid position from SEQ. ID No:
- 1 and the antagonist inhibits CEA-specific immune responses.
Dependencies are inferred from the claim text.